BXT-25
Acute Respiratory Distress Syndrome (ARDS)
Key Facts
About BioXyTran
BioXyTran is a clinical-stage biotech leveraging proprietary carbohydrate chemistry to develop therapeutics across two core platforms: antiviral entry inhibitors and oxygen transport molecules for hypoxia. Founded in 2014 and led by carbohydrate chemistry expert Dr. David Platt, the company is advancing its pipeline through preclinical and clinical development. Its strategy focuses on creating first-in-class treatments for large markets with high unmet need, including viral infections and ischemic conditions, aiming to deliver value through platform validation and strategic partnerships.
View full company profileAbout BioXyTran
BioXyTran is a clinical-stage biotech leveraging proprietary carbohydrate chemistry to develop therapeutics across two core platforms: antiviral entry inhibitors and oxygen transport molecules for hypoxia. Founded in 2014 and led by carbohydrate chemistry expert Dr. David Platt, the company is advancing its pipeline through preclinical and clinical development. Its strategy focuses on creating first-in-class treatments for large markets with high unmet need, including viral infections and ischemic conditions, aiming to deliver value through platform validation and strategic partnerships.
View full company profileAbout BioXyTran
BioXyTran is a clinical-stage biotech leveraging proprietary carbohydrate chemistry to develop therapeutics across two core platforms: antiviral entry inhibitors and oxygen transport molecules for hypoxia. Founded in 2014 and led by carbohydrate chemistry expert Dr. David Platt, the company is advancing its pipeline through preclinical and clinical development. Its strategy focuses on creating first-in-class treatments for large markets with high unmet need, including viral infections and ischemic conditions, aiming to deliver value through platform validation and strategic partnerships.
View full company profileAbout BioXyTran
BioXyTran is a clinical-stage biotech leveraging proprietary carbohydrate chemistry to develop therapeutics across two core platforms: antiviral entry inhibitors and oxygen transport molecules for hypoxia. Founded in 2014 and led by carbohydrate chemistry expert Dr. David Platt, the company is advancing its pipeline through preclinical and clinical development. Its strategy focuses on creating first-in-class treatments for large markets with high unmet need, including viral infections and ischemic conditions, aiming to deliver value through platform validation and strategic partnerships.
View full company profileTherapeutic Areas
Other Acute Respiratory Distress Syndrome (ARDS) Drugs
| Drug | Company | Phase |
|---|---|---|
| MultiStem | Athersys | Phase 3 |
| Bioengineered Surfactant Program | BioSuperior | Pre-clinical |
| FX06 | F4 Pharma | Phase 1/2 |
| AVM0703 | AVM Biotechnology | Pre-clinical / Research |
| ACE2v2-Fc | Cyrus Biotechnology | Preclinical |
| GEn-1124 | GEn1E Lifesciences | Phase 2 |
| AZM-152 | Azome Therapeutics | Pre-clinical |
| Zelpultide Alfa | Airway Therapeutics | Pre-clinical/Research |
| ALT-100 mAb | Aqualung Therapeutics | Phase 2a |
| RP-323 | PhorMed | Phase 2 |
| Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS | Sedana Medical | Investigator-Initiated Trial |
| Research Grant: Effects of sevoflurane on lung water in ARDS | Sedana Medical | Investigator-Initiated Trial |